Welcoming Dr. Natasha Hunter as Director of Clinical Trials at CVI

We are thrilled to announce that Dr. Natasha Hunter, MD, has been appointed Director of Clinical Trials at the Cancer Vaccine Institute (CVI).

Dr. Hunter is a translational breast cancer researcher and clinical oncologist at the University of Washington and Fred Hutchinson Cancer Center. Her research focuses on circulating tumor DNA to guide treatment decisions and monitor disease response, as well as immunologic strategies to detect micrometastatic disease and prevent cancer recurrence.

As Director of Clinical Trials, Dr. Hunter brings visionary leadership and deep clinical expertise to CVI’s vaccine development efforts. “We are thrilled to welcome Dr. Hunter to this pivotal role,” said Dr. Nora Disis, Director of CVI. “Her ability to bridge cutting-edge science with compassionate patient care will be instrumental as we expand our clinical trials program and bring innovative cancer vaccines to more people.” In addition to overseeing our clinical trials program, Dr. Hunter is also serving as principal investigator for several phase II clinical trials evaluating our vaccines in multiple cancer settings.

These trials represent critical steps in our mission to develop therapeutic cancer vaccines that improve outcomes and quality of life for patients. Dr. Hunter’s commitment to translational science and patient-centered care makes her an invaluable leader in this work.

Please join us in welcoming Dr. Hunter to her new role. Her leadership marks an exciting chapter for CVI as we advance innovative vaccines and immune therapies for cancer and expand access to clinical trials.

PC: Fred Hutch